Vor Biopharma Inc (NASDAQ:VOR) saw its stock climb 2.9% following news that its partner RemeGen Co., Ltd (USOTC:REGMY) successfully hit the primary endpoint in Stage A of a Phase 3 trial for telitacicept in adults with IgA nephropathy (IgAN).
The China-based study reported a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at 39 weeks compared to placebo (p<0.0001). The trial included 318 adult IgAN patients who had already received standard therapies.
“Telitacicept continues to demonstrate consistent, disease-modifying activity across autoimmune conditions, from myasthenia gravis to Sjögren’s disease and now IgA nephropathy,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board at Vor Bio.
Following the encouraging results, RemeGen plans to submit a Biologics License Application to China’s National Medical Products Administration. If approved, IgAN would become telitacicept’s fifth approved indication in China.
Vor Biopharma emphasized that detailed study results will be shared at an upcoming medical conference and reaffirmed its commitment to transforming the treatment of autoimmune diseases through its collaboration with RemeGen.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.